An exploratory, post hoc analysis was performed using data from a prospective, multicenter,
open‐label, randomized, two‐period (14 d per period), two‐sequence, crossover, steady …

Pharmacokinetic analyses comparing generic tacrolimus preparations versus the reference
drug in kidney transplant patients are lacking. A prospective, multicenter, open-label …

Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily
formulation (Tacrolimus BID). A once-daily prolonged-release formulation (Tacrolimus QD) …

Background There is a growing concern about the therapeutic equivalence of the generic
tacrolimus formulation (GEN Tacrolimus) to the reference tacrolimus (REF Tacrolimus) in …

Objectives The aims of this study were to investigate the population pharmacokinetics of
tacrolimus in adult kidney transplant recipients and to identify factors that explain variability …

Background Tacrolimus is a well-established immunosuppressive agent for the treatment
and prevention of solid organ graft rejection. It is available as an immediate-release, twice …

What is known and objective Tacrolimus, the most widely used calcineurin inhibitor in kidney
transplantation, has a narrow therapeutic window with high interindividual variability in its …

Background Scrupulous comparison of the pharmacokinetic and clinical characteristics of
generic tacrolimus formulations versus the reference drug (Prograf) is essential. The …

Background: The success of an immunosuppressive drug therapy depends on the extent of
exposure to the drugs (the blood levels and duration), which is measured as the area under …

Tacrolimus a macrolide immunosuppressant that is routinely given in two equally divided
doses every 12 h. However, the time‐dependent pharmacokinetics of tacrolimus suggest …